Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand (NASDAQ:DERM)March 26, 2026
Share Facebook Twitter LinkedIn Pinterest Email Earnings Snapshot: CrowdStrike beats Q4 estimates, but weak outlook weighs on stock
Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand (NASDAQ:DERM)March 26, 2026
Modiv Industrial outlines accelerated asset recycling, targets 100% manufacturing portfolio within 24 months (NYSE:MDV)March 26, 2026
By Press Room
By Press Room
By Press Room
